Laigo Bio
Health
· Headquartered in N/A 🌍
Track Laigo Bio
— get Health deals in free daily digest
Overview
Laigo Bio, a Utrecht-based biotech company developing therapies using its Suretac precision membrane protein degradation platform, has secured €11.5 million in seed funding. The round was co-led by Kurma Partners and Curie Capital, aimed at advancing treatments for autoimmune and inflammatory diseases. The company focuses on targeting previously "undruggable" proteins, demonstrating promising preclinical efficacy.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: Kurma Partners, Curie Capital
Laigo Bio, a Utrecht-based biotech company developing therapies using its Suretac precision membrane protein degradation platform, has secured €11.5 million in seed funding. The round was co-led by Kurma Partners and Curie Capital, aimed at advancing treatments for autoimmune and inflammatory diseases. The company focuses on targeting previously "undruggable" proteins, demonstrating promising preclinical efficacy.
More Health Deals
Market Map
View thousands of companies by category in our market map:
